Cover Image

Explainable AI and debiased networks: The ‘last mile’ for precision medicine delivery

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Siyi Liu, Zekai Yu
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	British Journal of Pharmacology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Network‐based precision medicine and systems pharmacology
by: Arvind K. Pandey, et al.
Published: (2025)

A deep neural network model for optimizing traditional Chinese medicine prescriptions with data augmentation
by: Xiaohan Mao, et al.
Published: (2025)

Application of paediatric cetirizine PBPK model to guide precision medicine and understand renal P‐glycoprotein ontogeny
by: Yafen Li, et al.
Published: (2026)

DysRegNet: Patient‐specific and confounder‐aware dysregulated network inference towards precision therapeutics
by: Johannes Kersting, et al.
Published: (2024)

The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases
by: Jiuguo Lin, et al.
Published: (2024)

A subtype‐selective photoswitchable agonist for precise manipulation of GABAA receptors
by: Simon Miguel M. Lopez, et al.
Published: (2025)

Network medicine and systems pharmacology approaches to predicting adverse drug effects
by: Alessio Funari, et al.
Published: (2024)

Exploring the antidepressant potential of Yueju Pill: Insights from traditional Chinese medicine
by: Xinyan Wu, et al.
Published: (2026)

Methodological considerations for a deep learning‐based prescription framework for traditional Chinese medicine
by: Mingze Ma, et al.
Published: (2026)

How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
by: Ralf Weiskirchen, et al.
Published: (2025)

Integrative immunomodulation in systemic autoimmune diseases: Mechanistic complementarity and therapeutic strategies of traditional Chinese and conventional medicine
by: Xiaomeng Zhang, et al.
Published: (2026)

Precision medicine in paediatrics: Progress and priorities
by: Nicola Husain, et al.
Published: (2026)

Clinical pharmacology in adolescent transgender medicine
by: Lauren R. Cirrincione, et al.
Published: (2024)

Section 19A in practice: Assessing the provision of overseas‐registered medicines to mitigate the impact of medicine shortages in Australia
by: Jack Janetzki, et al.
Published: (2025)

A high‐precision view of intercompartmental drug transport via simultaneous, seconds‐resolved, in situ measurements in the vein and brain
by: Julian Gerson, et al.
Published: (2024)

The clinical toxicity of advanced therapy medicinal products
by: Fraser J. H. Henderson, et al.
Published: (2025)

Innovations in pharmacovigilance studies of medicines in older people
by: Lisa M. Kalisch Ellett, et al.
Published: (2024)

Correction to “Evaluating the impact of general practice pharmacist‐led person‐centred medicines reviews on medicines appropriateness and patient‐reported outcome measures”
Published: (2026)

Morbimortality consequences of use and misuse of psychoactive medicines in Portugal
by: Ana Carmona Araújo, et al.
Published: (2025)

Assessment of clinical pharmacology and competence during medicine clerkships
by: Nicole C. Cheung, et al.
Published: (2025)

A comprehensive review of anti‐colorectal cancer alkaloids from traditional Chinese medicine: Sources, chemical structures, mechanisms and therapeutic applications
by: Kaiping Cong, et al.
Published: (2026)

Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation
by: Dominik Karres, et al.
Published: (2024)

Topical application of a P2X2/P2X3 purine receptor inhibitor suppresses the bitter taste of medicines and other taste qualities
by: Linda J. Flammer, et al.
Published: (2024)

Advanced therapy medicinal products (ATMPs) – An analysis of the global regulatory status
by: Allan Cramer, et al.
Published: (2026)

MCF classifier: Estimating, standardizing, and stratifying medicine carbon footprints, at scale
by: Haroon Taylor, et al.
Published: (2024)

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research
by: Titiaan E. Post, et al.
Published: (2024)

Correction to “Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice”
Published: (2025)

Model‐informed vancomycin precision dosing by population pharmacokinetics combined with machine learning algorithms
by: Lei Shi, et al.
Published: (2026)

Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency
by: Valentina Giunchi, et al.
Published: (2025)

A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU
by: Charlotte W. M. Simons, et al.
Published: (2025)

Patient preferences and attitudes regarding the environmental impact of medicines: A discrete choice experiment
by: Milad Sadreghaemy, et al.
Published: (2025)

Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross‐sectional study
by: Amelia Smith, et al.
Published: (2025)

Sustainable medicines development and use: Challenges and opportunities in the sustainable production of active pharmaceutical ingredients
by: Gary M. Noonan, et al.
Published: (2024)

System level network data and models attack cancer drug resistance
by: Márk Kerestély, et al.
Published: (2025)

The use of different types of networks, alone and in combination, for drug target identification
by: Paolo Parini
Published: (2025)

Systematic review and scoring‐based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children
by: Zoë Vander Elst, et al.
Published: (2026)

Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings
by: Monica Jung, et al.
Published: (2026)

Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report
by: Mariam Nersesjan, et al.
Published: (2024)

Cyclodextrin‐based delivery of Annexin A1 mimetic Ac2–26 enhances anti‐inflammatory effect and prevents dengue‐induced lethality combined with antiviral therapy
by: Jenniffer Ramos Martins, et al.
Published: (2026)

Targeted peptide‐modified M2 exosomes drug delivery system for the targeted regulation of the lung injury microenvironment with isorhynchophylline (IRN): based on the inflammatory–metabolic–epigenetic synergy mechanism
by: Jin‐Ru Zou, et al.
Published: (2026)